In 2021, Hangzhou DAC and WuXi Bio established a strategic partnership to jointly enable multiple innovative ADCs, leveraging Hangzhou DAC's proprietary payload and linker platform and WuXi Bio’s leading antibody discovery platform. The three ADC pre-clinical candidates granted to Aadi, utilizing Hangzhou DAC’s CrossConju™ ADC site-specific conjugation technology and Top1 payload-linker technology, have demonstrated promising efficacy and safety profile in various preclinical tumor models. These ADCs address significant unmet medical needs in lung cancer, gastrointestinal cancer, ovarian cancer and other major tumor indications.

“We are thrilled to announce this strategic collaboration with Aadi and WuXi Bio,” said Robert Y. Zhao, founder and CEO of Hangzhou DAC. “Aadi’s in-depth knowledge of precision oncology and expertise in clinical development will provide robust support for future development of these three ADC programs. Meanwhile, we look forward to advancing our strategic collaboration with WuXi Bio and developing more innovative ADCs.”

“Over the years, we have established partnerships with multiple international pharmaceutical companies by asset out-licensing or research collaboration. Hangzhou DAC’s CrossConju™ ADC site-specific conjugation technology and Top1 payload-linker platform have been applied and clinically validated in multiple collaborative and in-house conjugated drugs. In the future, we will continue to expand collaborations with global partners and accelerate the clinical development of in-house pipeline to provide better treatment options for patients worldwide,” Dr. Zhao continued.

“Leveraging our advanced antibody discovery service, we’re glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers,” said Dr. Chris Chen, CEO of WuXi Biologics. “This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide.”

“I’m thrilled to announce our partnership with WuXi Biologics and Hangzhou DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer,” said David Lennon, PhD, President and CEO of Aadi Bioscience.